GABSX
Price
$51.47
Change
-$0.18 (-0.35%)
Updated
Jul 31 closing price
Net Assets
1.86B
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

GABSX vs VSCIX

GABSX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
GABSX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GABSX is a Hold and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. GABSX (1.86B). VSCIX pays higher dividends than GABSX: VSCIX (1.23) vs GABSX (0.24). GABSX was incepted earlier than VSCIX: GABSX (35 years) vs VSCIX (29 years). GABSX (1.38) is less costly to investors than VSCIX (0.03). VSCIX is a more actively managed with annual turnover of: 17.00 vs. GABSX (1.00). GABSX has a lower initial minimum investment than VSCIX: GABSX (1000) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 22.58 vs. GABSX (16.58). VSCIX return over 5 years is better than : 35.13 vs. GABSX (2.61).
GABSXVSCIXGABSX / VSCIX
Total Expense Ratio1.380.034,600%
Annual Report Gross Expense Ratio1.380.034,600%
Fund Existence35 years29 years-
Gain YTD13.92214.59195%
Front LoadN/AN/A-
Min. Initial Investment100050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.86B189B1%
Annual Yield % from dividends0.241.2319%
Returns for 1 year16.5822.5873%
Returns for 3 years17.3343.4440%
Returns for 5 years2.6135.137%
Returns for 10 years5.70156.074%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C